Acoramidis Publications from BridgeBio Pharma and Bayer

European Society of Cardiology (ESC) 2025

Congress Dates: Aug 29 – Sept 1; Venue: Madrid, Spain

1. Improvement in NT-proBNP

Acoramidis-mediated improvement in NT-proBNP at Month 30 compared with placebo in patients with ATTR-CM: results from the ATTRibute-CM study

Session Details:

  • Number: 3860
  • Title: Cardiac amyloidosis
  • Location: Ex-change Circle 5 – Research Gateway

Presentation Date and Time:

  • Aug 31, 2025
  • 16:15 – 17:00 CEST

Nitasha Sarswat, Ahmad Masri, Kunal Bhatt, Michele Emdin, Emer Joyce, Michel Khouri, Kai Vogtländer, Jean-François Tamby, Adam Castaño, Jonathan C. Fox, Marianna Fontana, Julian D. Gillmore, Mazen Hanna, Pablo Garcia-Pavia

2. Stable/Improved NAC at Month 30

Acoramidis Has a Beneficial Effect Compared With Placebo on Change From Baseline in NAC ATTR Stage at Month 30 in Patients with ATTR-CM: Results From the ATTRibute-CM Study

Session Details:

  • Number: 3800
  • Title: New perspectives in cardiology (1)
  • Location: Discovery Pole - North Convention Centre

Presentation Date and Time:

  • Aug 29, 2025
  • 15:15 - 16:00 CEST

Julian D. Gillmore, Martha Grogan, Timothy Sutton, Matthias Dupont, Nowell M. Fine, Kunal Bhatt, Diego Delgado, Chris Chen, Jean-François Tamby, Suresh Siddhanti, Jonathan C. Fox, Marianna Fontana

3. OLE – CVM and CVM/First CVH analysis (M42)

Acoramidis reduces cardiovascular mortality (CVM): results at Month 42 from the ATTRibute-CM open-label extension (OLE) study

Session Details:

  • Number: 3075
  • Title: The evolving landscape of transthyretin amyloidosis
  • Location: Science Box 4 - Research Gateway

Presentation Date and Time:

  • Aug 30, 2025
  • 13:15 – 13:25 CEST

Kevin Alexander, Amrut V Ambardekar, Francesco Cappelli, Marianna Fontana, Ahmad Masri, Nitasha Sarswat, Keyur Shah, Prem Soman, Chris Chen, Jean-François Tamby, Jonathan C Fox, Mathew S Maurer

4. Improvement in NT-proBNP and 6MWD

Acoramidis leads to clinically meaningful improvements from baseline in NT-proBNP and 6-minute walk distance in patients with transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM

Session Details:

  • Number: 3417
  • Title: Treatment of transthyretin amyloidosis
  • Location: Station 8 - Research Gateway

Presentation Date and Time:

  • Sep 1, 2025
  • 11:15 – 12:00 CEST

Francesco Cappelli, Marianna Fontana, Teresa Coelho, Kai Vogtländer, Antonio Ciaccia, Jean-François Tamby, Jonathan C. Fox, Thibaud Damy, Daniel P. Judge, Ahmad Masri, Pablo Garcia-Pavia, Julian D. Gillmore

Copies of this presentation and associated educational materials obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from ESC, the authors of this poster, the sponsor of the study (BridgeBio Pharma, Inc.), and Bayer, specifically for the "Acoramidis leads to clinically meaningful improvements from baseline in NT-proBNP and 6-minute walk distance in patients with transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM" poster.